Aptevo Therapeutics Inc. (APVO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 4M 8M 12M Q1 '15: 11.7M Q2 '15: 7.1M Q3 '15: 6.6M Q4 '15: 8.3M Q1 '16: 8.1M Q2 '16: 10.2M Q3 '16: 2.8M Q4 '16: 8.8M Q1 '17: 2.1M Q2 '17: 3.5M Q3 '17: 6.2M Q4 '17: 2.8M Q1 '18: 4.1M Q2 '18: 6.8M Q3 '18: 5.8M Q4 '18: 6.3M Q1 '19: 7M Q2 '19: 7.4M Q3 '19: 9M Q4 '19: 9M Q2 '20: 473K Q3 '20: 1.5M Q4 '20: 2.4M Q1 '21: 2.4M Q2 '21: 3.1M Q3 '21: 3.1M Q4 '21: 3.7M Q1 '22: 3.1M Q2 '22: 0 Q3 '22: 0 Q4 '22: 0 Q3 '15 Q3 '16 Q3 '17 Q3 '18 Q3 '19 Q4 '20 Q4 '21 Q4 '22

Gross Profit Quarterly

0 2M 4M 6M Q1 '18: 2.3M Q2 '18: 4.3M Q3 '18: 3.4M Q4 '18: 1.9M Q1 '19: 3.2M Q2 '19: 1.4M Q3 '19: 5.1M Q4 '19: 2.9M Q1 '18 Q2 '18 Q3 '18 Q4 '18 Q1 '19 Q2 '19 Q3 '19 Q4 '19

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-105M -70M -35M 0 35M 70M 105M Q3 '16: -90.5M Q4 '16: -14.6M Q1 '17: -12.1M Q2 '17: -14.6M Q3 '17: -10.3M Q4 '17: -16.8M Q1 '18: -13.5M Q2 '18: -12.4M Q3 '18: -12.1M Q4 '18: -13.6M Q1 '19: -11.4M Q2 '19: -12.9M Q3 '19: -11.5M Q4 '19: -7.9M Q1 '20: -7.6M Q2 '20: -6.8M Q3 '20: -6.2M Q4 '20: -6.8M Q1 '21: -6.9M Q2 '21: -5.7M Q3 '21: -4.8M Q4 '21: -4M Q1 '22: -5.6M Q2 '22: -7.6M Q3 '22: -7.8M Q4 '22: -7.7M Q1 '23: -7.8M Q2 '23: -8.2M Q3 '23: -6.6M Q4 '23: -6.4M Q1 '24: -7M Q2 '24: -6M Q3 '24: -5.2M Q4 '24: -6.4M Q1 '25: -6.5M Q2 '25: -6.2M Q3 '25: -7.6M Q4 '25: -6M Q1 '26: -6.8M Q2 '26: -6.4M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '16: -71.7M Q4 '16: -14.9M Q1 '17: -9.9M Q2 '17: -11.2M Q3 '17: 37.9M Q4 '17: -9.8M Q1 '18: -13.9M Q2 '18: -13.1M Q3 '18: -12.6M Q4 '18: -14.1M Q1 '19: -12M Q2 '19: -13.3M Q3 '19: -6.9M Q4 '19: -8.2M Q1 '20: 2.9M Q2 '20: -6.8M Q3 '20: -6.8M Q4 '20: -7.1M Q1 '21: -7.3M Q2 '21: -7.9M Q3 '21: -7M Q4 '21: -6.3M Q1 '22: -7.7M Q2 '22: 28M Q3 '22: -7.6M Q4 '22: -4.6M Q1 '23: 2.8M Q2 '23: -7.9M Q3 '23: -6.3M Q4 '23: -5.9M Q1 '24: -6.8M Q2 '24: -5.9M Q3 '24: -5.1M Q4 '24: -6.3M Q1 '25: -6.4M Q2 '25: -6.2M Q3 '25: -7.5M Q4 '25: -5.8M Q1 '26: -6.7M Q2 '26: -6.4M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

0 2.5M 5M 7.5M Q1 '18: 1.8M Q2 '18: 2.5M Q3 '18: 2.4M Q4 '18: 4.5M Q1 '19: 3.8M Q2 '19: 6M Q3 '19: 4M Q4 '19: 6.1M Q1 '18 Q2 '18 Q3 '18 Q4 '18 Q1 '19 Q2 '19 Q3 '19 Q4 '19

Operating Cash Flow Quarterly

-18M -12M -6M 0 6M 12M 18M Q3 '16: -134K Q4 '16: -6.7M Q1 '17: -12M Q2 '17: -12.5M Q3 '17: -1.6M Q4 '17: -15.4M Q1 '18: -17M Q2 '18: -16M Q3 '18: -11.1M Q4 '18: -7.3M Q1 '19: -13.8M Q2 '19: -15.9M Q3 '19: -7.5M Q4 '19: -5.1M Q1 '20: -11.2M Q2 '20: -4.6M Q3 '20: -7.4M Q4 '20: -6.1M Q1 '21: -7.5M Q2 '21: -5.1M Q3 '21: -5.2M Q4 '21: -3.9M Q1 '22: -5.1M Q2 '22: -3.1M Q3 '22: -6.9M Q4 '22: -5.9M Q1 '23: 4.6M Q2 '23: -4.8M Q3 '23: -6.2M Q4 '23: -5.3M Q1 '24: -6.7M Q2 '24: -6.2M Q3 '24: -5.2M Q4 '24: -5.8M Q1 '25: -6.6M Q2 '25: -7.1M Q3 '25: -6.7M Q4 '25: -5.2M Q1 '26: -8M Q2 '26: -5.5M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-18M -12M -6M 0 6M 12M 18M Q3 '15: -9.8M Q4 '15: -8.2M Q1 '16: -15.2M Q2 '16: -16.9M Q3 '16: -180K Q4 '16: -7.2M Q1 '17: -12.8M Q2 '17: -12.7M Q3 '17: -1.8M Q4 '17: -15.7M Q1 '18: -17.5M Q2 '18: -16.1M Q3 '18: -11.5M Q4 '18: -7.3M Q1 '19: -14M Q2 '19: -15.9M Q3 '19: -7.5M Q4 '19: -5.1M Q1 '21: -7.7M Q2 '21: -5.4M Q3 '21: -5.3M Q4 '21: -4M Q3 '22: -6.9M Q4 '22: -5.9M Q1 '16 Q4 '16 Q3 '17 Q2 '18 Q1 '19 Q4 '19 Q3 '21 Q4 '22

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 8M 16M 24M Q3 '16: 20.2M Q1 '17: 20.8M Q2 '17: 21.3M Q3 '17: 21.7M Q1 '18: 22M Q2 '18: 22.6M Q3 '18: 22.7M Q2 '21: 4.5M Q3 '21: 4.9M Q1 '22: 4.9M Q2 '22: 5M Q3 '22: 5.1M Q1 '23: 159.6K Q2 '23: 147.3K Q3 '23: 285.9K Q1 '24: 18.6K Q2 '24: 4.8K Q3 '24: 14.3K Q1 '25: 4.1K Q2 '25: 41K Q3 '25: 4M Q1 '26: 1.1M Q2 '26: 1.2M Q1 '17 Q1 '18 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-45000.00 -30000.00 -15000.00 0.00 15000.00 30000.00 45000.00 Q4 '15: -2.93 Q1 '16: -3.03 Q2 '16: -2.78 Q3 '16: -5.70 Q4 '16: -5.56 Q1 '17: -5.40 Q2 '17: -5.30 Q3 '17: 0.00 Q4 '17: 0.33 Q1 '18: 0.18 Q2 '18: 0.13 Q3 '18: -2.18 Q4 '18: -2.39 Q1 '19: -9.40 Q2 '19: -12.96 Q3 '19: -14.55 Q4 '19: -16.31 Q1 '20: -7.78 Q2 '20: -5.74 Q3 '20: -5.69 Q4 '20: -5.23 Q1 '21: -7.76 Q2 '21: -7.41 Q3 '21: -6.74 Q4 '21: -6.09 Q1 '22: -6.00 Q2 '22: 1.33 Q3 '22: 1.26 Q4 '22: 1.57 Q1 '23: 20.50 Q2 '23: -39.03 Q3 '23: -59.69 Q4 '23: -2319.34 Q1 '24: -2704.93 Q2 '24: -3887.94 Q3 '24: -4223.64 Q4 '24: -29713.50 Q1 '25: -30927.10 Q2 '25: -29841.43 Q3 '25: -29485.80 Q4 '16 Q1 '18 Q2 '19 Q3 '20 Q4 '21 Q1 '23 Q2 '24 Q3 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.